Related references
Note: Only part of the references are listed.Gilbert's syndrome and irinotecan toxicity: Combination with UDP-glucuronosyltransferase 1A7 variants increases
Tim O. Lankisch et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2008)
Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFIRI chemotherapy
A. Ruzzo et al.
PHARMACOGENOMICS JOURNAL (2008)
Lack of association between common Polymorphisms in UGT1A9 and gene expression and activity
Jacqueline Ramirez et al.
DRUG METABOLISM AND DISPOSITION (2007)
Genetic linkage of UGT1A7 and UGT1A9 polymorphisms to UGT1A1*6 is associated with reduced activity for SN-38 in Japanese patients with cancer
Ken-Ichi Fujita et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2007)
Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy
Annamaria Ruzzo et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Pharmacogenetics of irinotecan: clinical perspectives on the utility of genotyping
Federico Innocenti et al.
PHARMACOGENOMICS (2006)
The role of UGT1A1*28 polymorphism in the pharmacodynarnics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer
Giuseppe Toffoli et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin
Ji-Youn Han et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Irinotecan inactivation is modulated by epigenetic silencing of UGT1A1 in colon cancer
JF Gagnon et al.
CLINICAL CANCER RESEARCH (2006)
Haplotypes of variants in the UDP-glucuronosyltransferase 1A9 and 1A1 genes
F Innocenti et al.
PHARMACOGENETICS AND GENOMICS (2005)
Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan
F Innocenti et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity:: A molecular and clinical study of 75 patients
E Rouits et al.
CLINICAL CANCER RESEARCH (2004)
Identification of common polymorphisms in the promoter of the UGT1A9 gene: evidence that UGT1A9 protein and activity levels are strongly genetically controlled in the liver
H Girard et al.
PHARMACOGENETICS (2004)
Glucuronidation as a mechanism of intrinsic drug resistance in colon cancer cells: contribution of drug transport proteins
J Cummings et al.
BIOCHEMICAL PHARMACOLOGY (2004)
A novel polymorphism in the promoter region of human UGT1A9 gene (UGT1A9*22) and its effects on the transcriptional activity
H Yamanaka et al.
PHARMACOGENETICS (2004)
Metastatic colorectal cancer: integrating irinotecan into combination and sequential chemotherapy
JY Douillard et al.
ANNALS OF ONCOLOGY (2003)
Haplotype structure of the UDP-glucuronosyltransferase 1A1 promoter in different ethnic groups
F Innocenti et al.
PHARMACOGENETICS (2002)
Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38)
JF Gagné et al.
MOLECULAR PHARMACOLOGY (2002)
Genetic polymorphisms of the UDP-glucuronosyltransferase 1A7 gene and irinotecan toxicity in Japanese cancer patients
M Ando et al.
JAPANESE JOURNAL OF CANCER RESEARCH (2002)
Enhanced clearance of topoisomerase I inhibitors from human colon cancer cells by glucuronidation
J Cummings et al.
BIOCHEMICAL PHARMACOLOGY (2002)
Structural heterogeneity at the UDP-glucuronosyltransferase 1 locus:: functional consequences of three novel missense mutations in the human UGT1A7 gene
C Guillemette et al.
PHARMACOGENETICS (2000)
Share Paper
